Mallinckrodt plc (NYSE: MNK) settled surge of 13.91% in recent trading period with closing price of $3.85. The company’s last traded volume of 11020888 shares vs to an average volume of 10468.65K shares. MNK has price to cash ratio of 1.34. In the trailing 12 months period, return on assets ratio of the corporation was -29.60% and return on equity ratio was -88.20% while its return on investment ratio was -36.70%.
Mallinckrodt plc (MNK) recently reported it has completed the sale of its wholly owned subsidiary BioVectra Inc. to an associate of H.I.G. Capital, a leading global private equity investment firm.
The terms of the transaction were updated since initial announcement, with total consideration of up to $250M including an upfront payment of $135M and contingent consideration of $115M based on the long-term performance of the business.
“This transaction marks an advancement of Mallinckrodt’s planned focus on branded, high-growth bio-pharmaceuticals,” stated Mark Trudeau, President and Chief Executive Officer. “While we recognize the longer-term growth potential of BioVectra, we believe this company will best achieve its potential under H.I.G. Capital, and we are confident that this sale will enable us to take part financially in the future success of the business.”
EPS growth for this year is -421.90% and EPS growth for next year is expected to reach at -11.60%. EPS growth in past five years was 4.35% while EPS growth in next five years is projected to arrive at -9.60%. Sales growth past 5 years was measured at 14.30%.